Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Gary Kirsh, MD
Advertisement
Kirsh is president emeritus of The Urology Group and chair of health policy for LUGPA.
Articles by Gary Kirsh, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Treating MIBC as a systemic disease reshapes bladder preservation
2
DASL-HiCaP Interim Results in Very High-Risk Localized Prostate Cancer
3
Durvalumab plus BCG may best serve patients with high-grade T1 NMIBC
4
William Huang, MD, discusses the potential of histotripsy for renal tumors
5